AMPHASTAR PHARMACEUTICALS IN (AMPH) Fundamental Analysis & Valuation

NASDAQ:AMPH • US03209R1032

19.96 USD
+0.13 (+0.66%)
At close: Mar 4, 2026
20.2 USD
+0.24 (+1.2%)
After Hours: 3/4/2026, 8:08:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AMPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 193 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH is valued quite cheap, but it does not seem to be growing. These ratings could make AMPH a good candidate for value investing.


Dividend Valuation Growth Profitability Health

8

1. AMPH Profitability Analysis

1.1 Basic Checks

  • In the past year AMPH was profitable.
  • AMPH had a positive operating cash flow in the past year.
  • AMPH had positive earnings in 4 of the past 5 years.
  • Of the past 5 years AMPH 4 years had a positive operating cash flow.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

  • The Return On Assets of AMPH (6.70%) is better than 88.08% of its industry peers.
  • AMPH has a better Return On Equity (14.37%) than 88.08% of its industry peers.
  • The Return On Invested Capital of AMPH (8.51%) is better than 88.08% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 12.91%.
  • The last Return On Invested Capital (8.51%) for AMPH is well below the 3 year average (12.92%), which needs to be investigated, but indicates that AMPH had better years and this may not be a problem.
Industry RankSector Rank
ROA 6.7%
ROE 14.37%
ROIC 8.51%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

  • The Profit Margin of AMPH (15.43%) is better than 87.56% of its industry peers.
  • In the last couple of years the Profit Margin of AMPH has grown nicely.
  • The Operating Margin of AMPH (20.73%) is better than 87.56% of its industry peers.
  • In the last couple of years the Operating Margin of AMPH has grown nicely.
  • AMPH has a Gross Margin of 49.36%. This is in the better half of the industry: AMPH outperforms 65.28% of its industry peers.
  • In the last couple of years the Gross Margin of AMPH has grown nicely.
Industry RankSector Rank
OM 20.73%
PM (TTM) 15.43%
GM 49.36%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AMPH Health Analysis

2.1 Basic Checks

  • AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for AMPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • AMPH has an Altman-Z score of 2.19. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AMPH has a Altman-Z score of 2.19. This is in the better half of the industry: AMPH outperforms 63.73% of its industry peers.
  • The Debt to FCF ratio of AMPH is 5.49, which is a neutral value as it means it would take AMPH, 5.49 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of AMPH (5.49) is better than 83.94% of its industry peers.
  • AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
  • AMPH's Debt to Equity ratio of 0.78 is on the low side compared to the rest of the industry. AMPH is outperformed by 68.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 5.49
Altman-Z 2.19
ROIC/WACC0.98
WACC8.71%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.12, AMPH is in line with its industry, outperforming 54.92% of the companies in the same industry.
  • AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • AMPH's Quick ratio of 2.21 is in line compared to the rest of the industry. AMPH outperforms 48.70% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.21
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. AMPH Growth Analysis

3.1 Past

  • The earnings per share for AMPH have decreased strongly by -15.80% in the last year.
  • AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 38.40% yearly.
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.83%

3.2 Future

  • Based on estimates for the next years, AMPH will show a decrease in Earnings Per Share. The EPS will decrease by -1.20% on average per year.
  • The Revenue is expected to grow by 4.48% on average over the next years.
EPS Next Y3.95%
EPS Next 2Y5%
EPS Next 3Y6.42%
EPS Next 5Y-1.2%
Revenue Next Year4.21%
Revenue Next 2Y4.51%
Revenue Next 3Y4.22%
Revenue Next 5Y4.48%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMPH Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.14, the valuation of AMPH can be described as very cheap.
  • Based on the Price/Earnings ratio, AMPH is valued cheaper than 94.82% of the companies in the same industry.
  • AMPH is valuated cheaply when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
  • AMPH is valuated cheaply with a Price/Forward Earnings ratio of 5.91.
  • Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 94.82% of the companies in the same industry.
  • AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.11.
Industry RankSector Rank
PE 6.14
Fwd PE 5.91
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 96.37% of the companies listed in the same industry.
  • AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 93.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.16
EV/EBITDA 5.79
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • AMPH's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)1.56
PEG (5Y)0.16
EPS Next 2Y5%
EPS Next 3Y6.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMPH Dividend Analysis

5.1 Amount

  • AMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPH Fundamentals: All Metrics, Ratios and Statistics

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (3/4/2026, 8:08:23 PM)

After market: 20.2 +0.24 (+1.2%)

19.96

+0.13 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-05
Inst Owners74.02%
Inst Owner Change-0.32%
Ins Owners9.38%
Ins Owner Change-0.09%
Market Cap905.59M
Revenue(TTM)N/A
Net Income(TTM)111.63M
Analysts76.92
Price Target32.2 (61.32%)
Short Float %10.9%
Short Ratio9.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)0%
PT rev (3m)-2.56%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)1.91%
EPS NY rev (1m)0%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.88%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)0.56%
Valuation
Industry RankSector Rank
PE 6.14
Fwd PE 5.91
P/S 1.25
P/FCF 8.16
P/OCF 5.95
P/B 1.17
P/tB 4.43
EV/EBITDA 5.79
EPS(TTM)3.25
EY16.28%
EPS(NY)3.38
Fwd EY16.93%
FCF(TTM)2.45
FCFY12.26%
OCF(TTM)3.36
OCFY16.82%
SpS15.94
BVpS17.12
TBVpS4.51
PEG (NY)1.56
PEG (5Y)0.16
Graham Number35.38
Profitability
Industry RankSector Rank
ROA 6.7%
ROE 14.37%
ROCE 10.26%
ROIC 8.51%
ROICexc 10.49%
ROICexgc 20.29%
OM 20.73%
PM (TTM) 15.43%
GM 49.36%
FCFM 15.35%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 5.49
Debt/EBITDA 3
Cap/Depr 78.19%
Cap/Sales 5.71%
Interest Coverage 6.36
Cash Conversion 75.12%
Profit Quality 99.44%
Current Ratio 3.12
Quick Ratio 2.21
Altman-Z 2.19
F-Score5
WACC8.71%
ROIC/WACC0.98
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
EPS Next Y3.95%
EPS Next 2Y5%
EPS Next 3Y6.42%
EPS Next 5Y-1.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.83%
Revenue Next Year4.21%
Revenue Next 2Y4.51%
Revenue Next 3Y4.22%
Revenue Next 5Y4.48%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.01%
EBIT Next 3Y0.12%
EBIT Next 5Y-1.03%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%

AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ

What is the fundamental rating for AMPH stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMPH.


What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?

ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.


Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.


What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6.14 and the Price/Book (PB) ratio is 1.17.